Publications by authors named "Steven Simoens"

Claim this Profile
T
The health production model and the crucial role of health promotion.
Lieven Annemans, Daan Aeyels, Gilbert Bejjani, Giovanni Briganti, Dirk Broeckx, Steven Simoens

Expert Rev Pharmacoecon Outcomes Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Barriers to adoption of biosimilar insulins in Europe: A mixed-methods study.
Elif Car, Garm Habets, Arnold G Vulto, Lutz Heinemann, Isabelle Huys, Steven Simoens

Diabetes Obes Metab· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Toward Regulatory Convergence and Streamlined Biosimilar Development: Recommendations from an International Qualitative Study.
Elif Car, Liese Barbier, Ingrid Schwarzenberger, Isabelle Huys, Steven Simoens

BioDrugs· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advanced therapy medicinal products are coming of age: A pipeline analysis of the clinical trial landscape.
Michiel Vanhaeren, Rik Gijsbers, Walter Van Dyck, Isabelle Huys, Steven Simoens

Drug Discov Today· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The unexploited potential of data systems tracking medicines utilization: an opportunity to improve access to oncology combination therapies.
Steven Simoens, David Dodwell, Michael Hartevelt, Peter Lindgren, Michele Pistollato

Front Pharmacol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preferences for gene therapy in Duchenne muscular dystrophy: insights from patient and caregiver interviews and attribute development.
Thomas Desmet, Lauren Van Haesendonck, Sophie Vermeire, Eline van Overbeeke, Steven Simoens

Front Pharmacol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: The unexploited potential of data systems tracking medicines utilization: an opportunity to improve access to oncology combination therapies.
Steven Simoens, David Dodwell, Michael Hartevelt, Peter Lindgren, Michele Pistollato

Front Pharmacol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Compulsory Licensing as an Instrument to Tackle High Medicine Prices: A Realist Review of Industrial and Health Consequences.
Steven Simoens, Walter Van Dyck, Rosanne Janssens, Liese Barbier, Jeroen Luyten

Appl Health Econ Health Policy· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Value attribution for oncology combination regimens: going beyond frameworks to balance innovation, access, and affordability.
Jennifer G Gaultney, Daniel Ollendorf, Medha Sasane, Céline Fernandez, Krupa Paranjpe, Steven Simoens

Front Pharmacol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolving global regulatory landscape for approval of biosimilars: current challenges and opportunities for convergence.
Elif Car, Liese Barbier, Isabelle Huys, Steven Simoens, Arnold G Vulto

Expert Opin Biol Ther· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the Cost-Effectiveness of Air Pollution Mitigation Strategies: A Systematic Review.
Bo Vandenbulcke, Nick Verhaeghe, Lisa Cruycke, Max Lelie, Steven Simoens

Int J Environ Res Public Health· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world cost-effectiveness of nirmatrelvir-ritonavir as treatment for SARS-CoV-2 infection in the Belgian setting with omicron variant.
Sophie Marbaix, Steven Simoens, Philippe Clevenbergh, Pascal Van Bleyenbergh, Keliane Liberman

Front Public Health· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness of Strategies Addressing Environmental Noise: A Systematic Literature Review.
Nick Verhaeghe, Bo Vandenbulcke, Max Lelie, Lieven Annemans, Steven Simoens

Int J Environ Res Public Health· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and Socioeconomic Burden of Retinal Diseases: Can Biosimilars Add Value? A Narrative Review.
Seenu M Hariprasad, Frank G Holz, Carl V Asche, Amine Issa, Oriol Mora, Steven Simoens

Ophthalmol Ther· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drawing on collective action theory to foster sustainable biosimilar markets - insights from co-creation workshops with UK and Belgian stakeholders.
Teresa Barcina Lacosta, Arnold G Vulto, Florian Turk, Isabelle Huys, Steven Simoens

Expert Opin Biol Ther· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Caregivers and multidisciplinary team members' perspectives on shared decision making in Duchenne muscular dystrophy: A qualitative study.
Elise Schoefs, Thomas Desmet, Evelyn Lerinckx, Liesbeth De Waele, Sam Geuens, Steven Simoens

Orphanet J Rare Dis· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
What role for real-world evidence in market access of biosimilars?
Steven Simoens, Catherine M Lockhart, Delphine F Courmier

Front Pharmacol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expert Consensus Recommendations on a Biosimilars Value Framework for the Gulf Cooperation Council Countries.
Khalid A Alnaqbi, Ahmed Al-Jedai, Mohamed Farghaly, Mohammed A Omair, Anas Hamad, Steven Simoens

Ther Innov Regul Sci· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Towards implementing new payment models for the reimbursement of high-cost, curative therapies in Europe: insights from semi-structured interviews.
Thomas Desmet, Sissel Michelsen, Elena Van den Brande, Walter Van Dyck, Steven Simoens

Front Pharmacol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Value based healthcare and Health Technology Assessment for emerging market countries: joint efforts to overcome barriers.
Maximillian Otte, Hans Peter Dauben, Jeonghoon Ahn, Iñaki Gutierrez Ibarluzea, Michael Drummond, Steven Simoens

Expert Rev Pharmacoecon Outcomes Res· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mitigating the Nocebo Effect in Biosimilar Use and Switching: A Systematic Review.
Elif Car, Yannick Vandenplas, Teresa Barcina Lacosta, Steven Simoens, Isabelle Huys

Pharmaceut Med· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The broader benefits of vaccines: methodologies for inclusion in economic evaluation.
Steven Simoens, Sandy Tubeuf, Nicolas Dauby, Olivier Ethgen, Sophie Marbaix

Expert Rev Vaccines· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Budget Impact of Disease-Modifying Treatments and a CRISPR Gene-Edited Therapy for Sickle Cell Disease.
Khadidja Abdallah, Isabelle Huys, Kathleen J Claes, Steven Simoens

Clin Drug Investig· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mapping Health Technology Assessment Agency Approaches for Biosimilar Value Assessment: An ISPOR Special Interest Group Report.
Teresa Barcina Lacosta, András Inotai, Catarina Lopes Pereira, Liese Barbier, Steven Simoens

Value Health· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis